|
NL270984A
(enExample)
|
1960-11-05 |
|
|
|
|
US3117160A
(en)
|
1961-07-27 |
1964-01-07 |
Pfizer & Co C |
Aralkylamines
|
|
US3198834A
(en)
|
1964-07-27 |
1965-08-03 |
Snc Science Union Et Compagnie |
Optical isomers of trifluoromethylated phenethylamines
|
|
GB1254332A
(en)
|
1969-02-27 |
1971-11-17 |
Science Union & Cie |
Amino acids and their derivatives and processes for preparing them
|
|
DE2143204C3
(de)
|
1971-08-28 |
1979-09-27 |
Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt |
N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
|
|
DE2150399A1
(de)
|
1971-10-09 |
1973-04-12 |
Hoechst Ag |
Neue oxime
|
|
GB1413070A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of - norfenfluramine and - fenfluramine and salts thereof
|
|
GB1413078A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
|
|
US4452815A
(en)
|
1980-06-16 |
1984-06-05 |
Massachusetts Institute Of Technology |
Method of utilizing d,l-fenfluramine for modifying feeding behavior
|
|
US4309445A
(en)
|
1980-06-16 |
1982-01-05 |
Massachusetts Institute Of Technology |
d-Fenfluramine for modifying feeding behavior
|
|
DE3717434C1
(de)
|
1987-05-23 |
1988-09-15 |
Degussa |
Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
|
|
US4857553A
(en)
|
1987-08-06 |
1989-08-15 |
A. H. Robins Company, Incorporated |
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
|
|
KR890003368A
(ko)
|
1987-08-06 |
1989-04-14 |
원본미기재 |
특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
|
|
HU204497B
(en)
|
1989-10-09 |
1992-01-28 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenfluramine
|
|
IT1238686B
(it)
|
1990-02-09 |
1993-09-01 |
Lab Mag Spa |
Procedimento per la preparazione di levo e destro fenfluramina
|
|
FR2663539B1
(fr)
|
1990-06-22 |
1994-10-07 |
Adir |
Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
|
|
FR2684552B1
(fr)
|
1991-12-06 |
1995-04-28 |
Adir |
Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
|
|
FR2685204B1
(fr)
|
1991-12-19 |
1995-06-16 |
Palmer Research |
Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
|
|
US5985880A
(en)
|
1996-06-05 |
1999-11-16 |
Delta Pharmaceuticals |
Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
|
|
DE69422044T2
(de)
|
1993-08-06 |
2000-05-31 |
Pharmacia & Upjohn Co., Kalamazoo |
2-aminoindane als selektive dopamin-d3-liganden
|
|
US5834477A
(en)
|
1993-12-08 |
1998-11-10 |
The United States Of America As Represented By The Secretary Of The Army |
Opiate analgesic formulation with improved safety
|
|
US5412102A
(en)
|
1994-05-27 |
1995-05-02 |
Syntex (U.S.A.) Inc. |
Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
|
|
ATE199829T1
(de)
|
1994-06-03 |
2001-04-15 |
Thejmde Trust |
Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
|
|
IT1298349B1
(it)
|
1996-05-29 |
2000-01-05 |
Alfa Chem Ital |
Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
|
|
IT1292885B1
(it)
|
1997-04-28 |
1999-02-11 |
Alfa Chem Ital |
Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
|
|
EP0920864A1
(en)
|
1997-12-03 |
1999-06-09 |
Pfizer Products Inc. |
Combination therapy including a specific beta-3 agonist and an anorectic agent
|
|
US20020098175A1
(en)
|
1998-06-16 |
2002-07-25 |
Zohoungbogbo Mathias C. |
Dietetic food composition and dietetic method using such composition
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
US6472431B2
(en)
|
1998-12-23 |
2002-10-29 |
Orphan Medical, Inc. |
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US7124031B1
(en)
|
2000-05-11 |
2006-10-17 |
Medco Health Solutions, Inc. |
System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
|
|
US20020032581A1
(en)
|
2000-07-17 |
2002-03-14 |
Reitberg Donald P. |
Single-patient drug trials used with accumulated database: risk of habituation
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
CA2446904A1
(en)
|
2001-05-24 |
2003-04-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of drug esters through an inhalation route
|
|
US7714020B2
(en)
|
2001-05-24 |
2010-05-11 |
Neuren Pharmaceuticals Limited |
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
|
|
CA2449613A1
(en)
|
2001-06-22 |
2003-01-03 |
Universite Catholique De Louvain |
Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
|
|
CA2455939C
(en)
|
2001-07-31 |
2011-03-22 |
Wyeth Llc |
Sucralose formulations to mask unpleasant tastes
|
|
AUPR732601A0
(en)
|
2001-08-28 |
2001-09-20 |
Polychip Pharmaceuticals Pty Ltd |
Methods for the synthesis of amines such as ephedrine and inter mediates
|
|
BR0212985A
(pt)
|
2001-09-24 |
2005-08-30 |
Imp College Innovations Ltd |
Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
|
|
RU2317104C2
(ru)
|
2001-09-24 |
2008-02-20 |
Импиэриэл Инноувейшнс Лимитид |
Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
|
|
US6599901B1
(en)
|
2001-11-19 |
2003-07-29 |
Hoffman-La Roche Inc. |
Pyridone substituted benzothiazole derivatives
|
|
US7101572B2
(en)
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
|
JP3813152B2
(ja)
|
2002-03-12 |
2006-08-23 |
メルク エンド カムパニー インコーポレーテッド |
置換アミド類
|
|
AU2003225964B2
(en)
|
2002-03-28 |
2008-11-20 |
Merck Sharp & Dohme Corp. |
Substituted 2,3-diphenyl pyridines
|
|
US7668730B2
(en)
|
2002-12-17 |
2010-02-23 |
JPI Commercial, LLC. |
Sensitive drug distribution system and method
|
|
WO2005004865A1
(en)
|
2003-07-08 |
2005-01-20 |
Georg-August-Universität Göttingen |
Use of 5-ht4(a)-serotonin receptor agonists
|
|
GB0410266D0
(en)
|
2004-05-07 |
2004-06-09 |
Ketocytonyx Inc |
Treatment of apoptosis
|
|
US20050260610A1
(en)
|
2004-05-20 |
2005-11-24 |
Kurtz Richard E |
Method for diagnosing and prescribing a regimen of therapy for human health risk
|
|
US9820658B2
(en)
|
2006-06-30 |
2017-11-21 |
Bao Q. Tran |
Systems and methods for providing interoperability among healthcare devices
|
|
AU2005286672B2
(en)
|
2004-09-23 |
2009-03-12 |
Merz Pharma Gmbh & Co. Kgaa |
Memantine for the treatment of childhood behavioral disorders
|
|
CN100567252C
(zh)
|
2004-10-11 |
2009-12-09 |
俞锋 |
盐酸芬氟拉明原料药和片剂及其制备方法
|
|
US20090216132A1
(en)
|
2005-03-21 |
2009-08-27 |
Tuvi Orbach |
System for Continuous Blood Pressure Monitoring
|
|
RU2007148444A
(ru)
|
2005-05-25 |
2009-06-27 |
Янссен Фармацевтика Н.В. (Be) |
Педиатрическая композиция топирамата
|
|
CA2607598A1
(en)
|
2005-06-06 |
2006-12-14 |
University Of South Florida |
Treatment with sigma receptor agonists post-stroke
|
|
EP1904630A4
(en)
|
2005-06-16 |
2009-10-21 |
Bionomics Ltd |
METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
|
|
GB0515090D0
(en)
|
2005-07-22 |
2005-08-31 |
Birmingham Res & Dev Ltd |
Novel epilepsy treatment
|
|
WO2007031846A2
(en)
|
2005-09-14 |
2007-03-22 |
University Of The Witwatersrand, Johannesburg |
Pharmaceutical composition
|
|
CA2622967A1
(en)
|
2005-09-19 |
2007-03-29 |
Biolert Ltd. |
A system and method for detecting an epileptic event
|
|
EP3223182A1
(en)
|
2005-11-29 |
2017-09-27 |
Children's Hospital Medical Center |
Optimization and individualization of medication selection and dosing
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
WO2007079181A2
(en)
|
2005-12-28 |
2007-07-12 |
Neurovista Corporation |
Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
|
|
BRPI0707518A2
(pt)
|
2006-02-06 |
2011-05-10 |
Novartis Ag |
combinaÇço de compostos orgÂnicos
|
|
DE102006030113B4
(de)
|
2006-06-28 |
2009-02-12 |
Chemische Fabrik Budenheim Kg |
Graphitfreier Hochtemperatur-Schmierstoff
|
|
EP2053961A4
(en)
|
2006-08-09 |
2013-05-01 |
Biogen Idec Inc |
METHOD FOR DISPENSING A MEDICAMENT
|
|
US8039468B2
(en)
|
2006-08-31 |
2011-10-18 |
The Governors Of The University Of Alberta |
Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
|
|
EP2115540A4
(en)
|
2007-01-31 |
2011-02-02 |
Quintiles Transnat Corp Inc |
METHOD AND SYSTEMS FOR ASSIGNING REPRESENTATIVE ELEMENTS TO LOCATIONS IN CLINICAL ATTEMPTS
|
|
EP2139467B1
(en)
|
2007-02-08 |
2016-09-21 |
Biogen MA Inc. |
Neuroprotection in demyelinating diseases
|
|
WO2008104524A1
(en)
|
2007-02-28 |
2008-09-04 |
Smithkline Beecham Corporation |
Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
|
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
EP3090743A1
(en)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions for treating headache and eliminating nausea
|
|
JP2011529923A
(ja)
|
2008-08-06 |
2011-12-15 |
ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド |
精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
|
|
WO2010020585A1
(en)
|
2008-08-18 |
2010-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin reuptake inhibitors for the treatment of rett syndrome
|
|
HUE043278T2
(hu)
|
2008-09-05 |
2019-08-28 |
Gruenenthal Gmbh |
3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció
|
|
US8386274B1
(en)
|
2008-09-17 |
2013-02-26 |
Mckesson Financial Holdings Limited |
Systems and methods for a prescription safety network utilizing eligibility verification transactions
|
|
MX2011003695A
(es)
|
2008-10-09 |
2011-08-17 |
A F S P A Aziende Chimiche Riunite Angelini Francesco A C R |
Formulacion farmaceutica liquida con contenido de paracetamol.
|
|
EP2355818A4
(en)
|
2008-10-10 |
2012-04-11 |
Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res |
METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
|
|
TWI424832B
(zh)
|
2008-12-15 |
2014-02-01 |
Proteus Digital Health Inc |
與身體有關的接收器及其方法
|
|
WO2010104841A2
(en)
|
2009-03-09 |
2010-09-16 |
Celgene Corporation |
Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
|
|
AU2010236404B2
(en)
|
2009-04-15 |
2016-11-03 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
|
WO2010124137A1
(en)
|
2009-04-22 |
2010-10-28 |
Millennium Pharmacy Systems, Inc. |
Pharmacy management and administration with bedside real-time medical event data collection
|
|
US9453027B2
(en)
|
2009-07-27 |
2016-09-27 |
Daljit Singh Dhanoa |
Deuterium-enriched pyridinonecarboxamides and derivatives
|
|
US20110212171A1
(en)
|
2010-01-08 |
2011-09-01 |
Eurand, Inc. |
Taste masked topiramate composition and an orally disintegrating tablet comprising the same
|
|
EP3255574A1
(en)
|
2010-03-09 |
2017-12-13 |
Perceptimed, Inc. |
Medication verification and dispensing
|
|
WO2011119227A2
(en)
|
2010-03-25 |
2011-09-29 |
Columbia Northwest Pharmaceuticals, Llc |
Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
|
|
JP2011221623A
(ja)
|
2010-04-06 |
2011-11-04 |
Kakimori Suri |
在宅診療支援システム及び方法
|
|
JP2013526583A
(ja)
|
2010-05-21 |
2013-06-24 |
リサーチ・トライアングル・インスティチュート |
フェニルモルホリンおよびその類似体
|
|
EP2399513B1
(en)
|
2010-06-23 |
2017-01-04 |
Qatar University Qstp-B |
System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
|
|
CA2805760A1
(en)
|
2010-07-30 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
Inhibition of cyp3a drug metabolism
|
|
KR20180118801A
(ko)
|
2010-09-01 |
2018-10-31 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
|
|
US20120270848A1
(en)
|
2010-10-22 |
2012-10-25 |
Galleon Pharmaceuticals, Inc. |
Novel Compositions and Therapeutic Methods Using Same
|
|
KR20160017668A
(ko)
|
2010-10-26 |
2016-02-16 |
알파마 파머슈티컬스 엘엘씨 |
오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
|
|
RU103209U1
(ru)
|
2010-10-29 |
2011-03-27 |
Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" |
Клиническая информационная система
|
|
GB2487712B
(en)
|
2011-01-04 |
2015-10-28 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
|
|
US10183008B2
(en)
|
2011-02-09 |
2019-01-22 |
University Of South Carolina |
Treatment of prolonged status epilepticus
|
|
JP5693325B2
(ja)
|
2011-03-29 |
2015-04-01 |
小林クリエイト株式会社 |
健診結果出力システム及び健診結果出力プログラム
|
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
US10092750B2
(en)
|
2011-11-11 |
2018-10-09 |
Neuroenabling Technologies, Inc. |
Transcutaneous neuromodulation system and methods of using same
|
|
US20140348966A1
(en)
|
2011-12-22 |
2014-11-27 |
Onesmo B. Balemba |
Garcinia buchananii baker compounds, compositions and related methods
|
|
EP2806867A4
(en)
|
2012-01-27 |
2015-09-02 |
Catalyst Pharmaceutical Partners Inc |
METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
|
|
WO2013122897A1
(en)
|
2012-02-13 |
2013-08-22 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
US20130218586A1
(en)
|
2012-02-21 |
2013-08-22 |
Frederic J. Huser |
Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
|
|
JP6075973B2
(ja)
|
2012-06-04 |
2017-02-08 |
富士通株式会社 |
健康状態判定装置およびその作動方法
|
|
SG11201503505QA
(en)
|
2012-11-15 |
2015-06-29 |
Galleon Pharmaceuticals Inc |
Novel orally bioavailable breathing control modulating compounds, and methods of using same
|
|
WO2014106825A2
(en)
|
2013-01-06 |
2014-07-10 |
Jonathan Rabinowitz |
Methods and devices for identifying improper medical reporting
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
EP3024463B1
(en)
|
2013-07-25 |
2020-03-25 |
Neuren Pharmaceuticals Limited |
Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
|
|
EP3636264A1
(en)
|
2013-08-19 |
2020-04-15 |
The Regents of the University of California |
Compounds and methods for treating an epileptic disorder
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
US20150141415A1
(en)
|
2013-11-20 |
2015-05-21 |
Omonike Arike Olaleye |
Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
|
|
CN103886415A
(zh)
|
2014-03-25 |
2014-06-25 |
北京蝶禾谊安信息技术有限公司 |
药品管理方法和装置
|
|
US20170089924A1
(en)
|
2014-04-22 |
2017-03-30 |
Tohoku University |
Method of testing for pulmonary hypertension
|
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
US10849518B2
(en)
|
2014-06-30 |
2020-12-01 |
University Of Cincinnati |
Non-invasive detection of spreading depolarization using scalp electroencephalography
|
|
MX378188B
(es)
|
2014-09-29 |
2025-03-10 |
Zogenix International Ltd |
Sistema de control para el control de distribucion de medicacion.
|
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
IL252848B2
(en)
|
2015-02-06 |
2024-07-01 |
Marinus Pharmaceuticals Inc |
Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders
|
|
HUE059559T2
(hu)
|
2015-02-25 |
2022-12-28 |
Univ California |
5HT agonisták az epilepsziás rendellenességek kezelésére
|
|
US10292996B2
(en)
|
2015-03-26 |
2019-05-21 |
The Trustees Of Columbia University In The City Of New York |
Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
|
|
CN104800168A
(zh)
|
2015-04-08 |
2015-07-29 |
石家庄四药有限公司 |
司替戊醇干混悬剂及其制备方法
|
|
JP6668045B2
(ja)
|
2015-05-15 |
2020-03-18 |
ゾゲニクス インターナショナル リミテッド |
ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
|
|
CN107847512A
(zh)
|
2015-06-17 |
2018-03-27 |
纽约市哥伦比亚大学理事会 |
用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法
|
|
EP3316890B1
(en)
|
2015-06-30 |
2023-09-06 |
Neurad Ltd. |
Novel breathing control modulating compounds, and methods of making and using same
|
|
ES2925951T3
(es)
|
2015-07-22 |
2022-10-20 |
John Hsu |
Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
|
|
EP3340971B1
(en)
|
2015-08-24 |
2024-03-13 |
Zogenix International Limited |
Methods of treating lennox-gastaut syndrome using fenfluramine
|
|
US20220193082A1
(en)
|
2015-09-14 |
2022-06-23 |
Zogenix International Limited |
Combination treatment of specific forms of epilepsy
|
|
US20170071949A1
(en)
|
2015-09-14 |
2017-03-16 |
Zogenix International Limited |
Combination treatment of specific forms of epilepsy
|
|
EP3170807B1
(en)
|
2015-11-23 |
2019-12-11 |
Frau Pharma S.r.l. |
New method for synthesis of fenfluramine
|
|
WO2017112701A1
(en)
|
2015-12-22 |
2017-06-29 |
Zogenix International Limited |
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
HUE053114T2
(hu)
|
2015-12-22 |
2021-06-28 |
Zogenix International Ltd |
Fenfluramin kompozíciók és eljárások azok elõállítására
|
|
JP6753418B2
(ja)
|
2016-01-14 |
2020-09-09 |
Ａｇｃ株式会社 |
フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
|
|
ES2882175T3
(es)
|
2016-03-28 |
2021-12-01 |
Takeda Pharmaceuticals Co |
Compuestos para su uso en el tratamiento de la hipertensión pulmonar
|
|
US20190083425A1
(en)
|
2016-08-24 |
2019-03-21 |
Zogenix International Limited |
Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
|
|
WO2018037306A1
(en)
|
2016-08-24 |
2018-03-01 |
Zogenix International Limited |
Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
|
|
US20180092864A1
(en)
|
2016-09-30 |
2018-04-05 |
Zogenix International Limited |
Compositions and methods for treating seizure disorders
|
|
CA3051699A1
(en)
|
2017-02-08 |
2018-08-16 |
Ovid Therapeutics Inc. |
Methods of treating seizure disorders and prader-willi syndrome
|
|
EP3634392A1
(en)
|
2017-05-09 |
2020-04-15 |
Zogenix International Limited |
Methods of treating doose syndrome using fenfluramine
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
US20190091176A1
(en)
|
2017-09-26 |
2019-03-28 |
Zogenix International Limited |
Method of treating selected patient population experiencing dravet syndrome
|
|
US20190247333A1
(en)
|
2017-09-26 |
2019-08-15 |
Zogenix International Limited |
Method of reduction in convulsive seizure frequency
|
|
WO2019067413A1
(en)
|
2017-09-26 |
2019-04-04 |
Zogenix International Limited |
USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
|
|
US20190091179A1
(en)
|
2017-09-26 |
2019-03-28 |
Zogenix International Limited |
Congnitive function with fenfluramine
|
|
GB201715919D0
(en)
|
2017-09-29 |
2017-11-15 |
Gw Res Ltd |
use of cannabinoids in the treatment of epilepsy
|
|
JP7769355B2
(ja)
|
2018-04-18 |
2025-11-13 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
ミトコンドリアｄｎａ枯渇症候群を含む不均衡ヌクレオチドプールに起因する疾患の遺伝子治療
|
|
CA3097335A1
(en)
|
2018-05-11 |
2019-11-14 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
EP3806835A1
(en)
|
2018-06-14 |
2021-04-21 |
Zogenix International Limited |
Compositions and methods for treating respiratory depression with fenfluramine
|
|
JP2021530481A
(ja)
|
2018-07-10 |
2021-11-11 |
ゾゲニクス インターナショナル リミテッド |
肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
|
|
KR20210061332A
(ko)
|
2018-07-27 |
2021-05-27 |
제논 파마슈티칼스 인크. |
뇌전증 치료 방법
|
|
SG11202104378SA
(en)
|
2018-11-19 |
2021-05-28 |
Zogenix International Ltd |
Methods of treating rett syndrome using fenfluramine
|
|
EP3887481A4
(en)
|
2018-11-30 |
2022-08-03 |
Zogenix International Limited |
METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
|
|
JP2022521446A
(ja)
|
2019-02-25 |
2022-04-07 |
ゾゲニクス インターナショナル リミテッド |
発作制御を改善するための製剤
|
|
US20210299064A1
(en)
|
2020-02-05 |
2021-09-30 |
Zogenix International Limited |
Method of treating patients with lennox-gastaut syndrome
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
US20220096514A1
(en)
|
2020-09-29 |
2022-03-31 |
Zogenix International Limited |
Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
|
|
EP4395753A4
(en)
|
2021-09-01 |
2025-05-07 |
Zogenix International Limited |
Fenfluramine for treatment of demyelinating diseases and conditions
|
|
WO2023101866A1
(en)
|
2021-12-01 |
2023-06-08 |
Zogenix International Limited |
Fenfluramine for treatment of conditions associated with spreading depolarization
|